Page last updated: 2024-08-18

allylamine and Parkinson Disease, Secondary

allylamine has been researched along with Parkinson Disease, Secondary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gibb, WR; Jackson, EA; Jenner, P; Marsden, CD; Nomoto, M; Rose, S	1

Other Studies

1 other study(ies) available for allylamine and Parkinson Disease, Secondary

Article	Year
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets. Neuropharmacology, 1989, Volume: 28, Issue:11 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allylamine; Animals; Behavior, Animal; Biogenic Amines; Callitrichinae; Caudate Nucleus; Dopamine; Female; Homovanillic Acid; Male; Monoamine Oxidase Inhibitors; Nucleus Accumbens; Parkinson Disease, Secondary; Putamen; Septal Nuclei	1989

Article

Year

Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.

Neuropharmacology, 1989, Volume: 28, Issue:11

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allylamine; Animals; Behavior, Animal; Biogenic Amines; Callitrichinae; Caudate Nucleus; Dopamine; Female; Homovanillic Acid; Male; Monoamine Oxidase Inhibitors; Nucleus Accumbens; Parkinson Disease, Secondary; Putamen; Septal Nuclei

1989